GT Biopharma Initiated Dosing In Cohort 3 Of Its Phase 1 Dose Escalation Trial Of GTB-3650 For Relapsed Or Refractory CD33 Expressing Hematologic Malignancies, Plans On Releasing Initial Phase 1 Results Later In 2025 Following Completion Of Additional Dose Cohorts
Benzinga Newsdesk 1 year ago
BiotechHealth CareGeneral
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed.The company plans
- The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed.
- The company plans on releasing initial Phase 1 results later in 2025 following completion of additional dose cohorts